Cargando…
Circulating tumor DNA analysis in the era of precision oncology
The spatial and temporal genomic heterogeneity of various tumor types and advances in technology have stimulated the development of circulating tumor DNA (ctDNA) genotyping. ctDNA was developed as a non-invasive, cost-effective alternative to tumor biopsy when such biopsy is associated with signific...
Autores principales: | Said, Rabih, Guibert, Nicolas, Oxnard, Geoffrey R., Tsimberidou, Apostolia M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968778/ https://www.ncbi.nlm.nih.gov/pubmed/32010431 http://dx.doi.org/10.18632/oncotarget.27418 |
Ejemplares similares
-
Clinical trial design in the era of precision medicine
por: Fountzilas, Elena, et al.
Publicado: (2022) -
Precision Oncology: Evolving Clinical Trials across Tumor Types
por: Song, I-Wen, et al.
Publicado: (2023) -
Clinical Circulating Tumor DNA Testing for Precision Oncology
por: Kim, Hyunji, et al.
Publicado: (2023) -
Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers
por: Addanki, Sridevi, et al.
Publicado: (2022) -
Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits
por: Fountzilas, Elena, et al.
Publicado: (2018)